SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

KROS

Keros Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The revenue collapse and EPS miss confirm Keros is a pre-revenue clinical-stage biotech with no approved products. The Takeda partnership provides a potential catalyst but no near-term revenue. Monitor for elritercept Phase 3 data and any pipeline updates; the cash runway provides a floor but the stock is likely to trade on binary trial outcomes.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.99
T+0 close · May 14, 2026 · via day close
Latest settled
−2.73%
T+60 · $10.69
Vs SPY
−6.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $10.99entry
  2. T+1 · 6mo ago −4.46%α −3.23% · $10.50
  3. T+5 · 6mo ago +2.09%α +2.81% · $11.22
  4. T+20 · 5mo ago −7.64%α −6.79% · $10.15
  5. T+60 · 3mo ago −2.73%α −6.32% · $10.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% below the $1.7M estimate. The net loss of $23.7M compares to net income of $148.5M in Q1 2025, driven by the absence of Takeda license revenue and reduced R&D spend. Cash runway extends into H1 2028, but the revenue collapse and EPS miss signal a pre-commercial biotech with no near-term catalysts beyond Takeda's Phase 3 plans.

Key Financial Metrics

EPS
−$1.21
est −$0.92 · -31.5%
Revenue
$367.0K
est $1.7M · -78.4% · -99.8% YoY
Rating
strong miss

Key Facts

  • Q1 2026 EPS of -$1.21 missed consensus of -$0.92 by 31.5%
  • Q1 2026 revenue of $0.367M missed consensus of $1.7M by 78.4%
  • Net loss of $23.7M vs net income of $148.5M in Q1 2025
  • Revenue collapsed 99.8% YoY due to absence of Takeda license revenue
  • Cash and equivalents $281.5M, expected runway into H1 2028
  • Takeda plans Phase 3 trial for elritercept in myelofibrosis anemia
  • Weighted-average shares outstanding fell to 19.6M from 40.6M YoY due to treasury stock

Financial Impact

EPS miss of $0.29 (31.5%) and revenue miss of $1.33M (78.4%) on a $237M market cap

revenueepsnet income

Risk Factors

  • No approved products or recurring revenue stream
  • Dependence on Takeda partnership for elritercept development
  • Clinical trial failure risk for rinvatercept and elritercept
  • Dilution risk from potential future equity offerings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294851

Track record

27 reports on KROS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026